An ETFDH-driven metabolon supports OXPHOS efficiency in skeletal muscle by regulating coenzyme Q homeostasis.

Coenzyme Q (Q) is a key lipid electron transporter, but several aspects of its biosynthesis and redox homeostasis remain undefined. Various flavoproteins reduce ubiquinone (oxidized form of Q) to ubiquinol (QH2); however, in eukaryotes, only oxidative phosphorylation (OXPHOS) complex III (CIII) oxid...

Descripción completa

Detalles Bibliográficos
Autores: Herrero Martín, Juan Cruz, Salegi Ansa, Beñat, Álvarez-Rivera, Gerardo, Domínguez-Zorita, Sonia, Rodríguez-Pombo, Pilar, Pérez, Belén, Calvo, Enrique, Paradela, Alberto, Miguez, David G, Cifuentes, Alejandro, Cuezva, José M, Formentini, Laura
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/20032
Acceso en línea:http://hdl.handle.net/20.500.12105/20032
Access Level:acceso abierto
Palabra clave:Electron-Transferring Flavoproteins
Oxidative Phosphorylation
Ubiquinone
Animals
Mice
Homeostasis
Lipids
Muscle, Skeletal
Descripción
Sumario:Coenzyme Q (Q) is a key lipid electron transporter, but several aspects of its biosynthesis and redox homeostasis remain undefined. Various flavoproteins reduce ubiquinone (oxidized form of Q) to ubiquinol (QH2); however, in eukaryotes, only oxidative phosphorylation (OXPHOS) complex III (CIII) oxidizes QH2 to Q. The mechanism of action of CIII is still debated. Herein, we show that the Q reductase electron-transfer flavoprotein dehydrogenase (ETFDH) is essential for CIII activity in skeletal muscle. We identify a complex (comprising ETFDH, CIII and the Q-biosynthesis regulator COQ2) that directs electrons from lipid substrates to the respiratory chain, thereby reducing electron leaks and reactive oxygen species production. This metabolon maintains total Q levels, minimizes QH2-reductive stress and improves OXPHOS efficiency. Muscle-specific Etfdh-/- mice develop myopathy due to CIII dysfunction, indicating that ETFDH is a required OXPHOS component and a potential therapeutic target for mitochondrial redox medicine.